Journal of Pharmacy Technology最新文献

{"title":"Pharmacist-Led Empiric Piperacillin-Tazobactam De-escalation Among Patients With Community-Acquired Intra-abdominal Infections.","authors":"Dolapo S Awobusuyi, Kevin Epps, Julio Mendez, Courtney Willis","doi":"10.1177/87551225251389431","DOIUrl":"10.1177/87551225251389431","url":null,"abstract":"<p><p><b>Background:</b> Piperacillin-Tazobactam (PTZ) is often used to treat community-acquired intra-abdominal infections (CA-IAIs) despite common causative pathogens being susceptible to more narrow-spectrum agents. However, susceptibility to PTZ among these predominant pathogens has been declining. Antibiotic de-escalation to non-antipseudomonal beta-lactams whenever possible is an important strategy to prevent the development of resistance to PTZ. <b>Objective:</b> The purpose of this study is to assess PTZ length of therapy in patients with CA-IAI, by comparing patients who received a pharmacist-led intervention involving the de-escalation of PTZ to narrow-spectrum regimens with those who did not receive the intervention. <b>Methods:</b> A retrospective analysis was conducted among patients >18 years old and admitted with CA-IAI empirically placed on PTZ between January 1, 2022, through June 30, 2022 (pre-intervention group), and January 1, 2024, through June 30, 2024 (post-intervention group). A total of 246 patients were included in the pre-intervention group and 129 patients in the post-intervention group. The utilization of PTZ, hospital length of stay (LOS), and treatment-associated complications were assessed using linear and logistic regression model, respectively. <b>Results:</b> Compared with patients in the pre-intervention group, those in the post-intervention group had a mean 1.2-day reduction in PTZ length of therapy (2.3 vs 1.2 days, <i>P</i> < 0.001). There was no difference in LOS, (β = 0.001, 98% confidence interval [CI] -1.29 to 1.29; <i>P</i> = 0.477), hospital readmission within 30 days due to IAI (odds ratio [OR] = 0.85, 98% CI = 0.51 to 1.44; <i>P</i> = 0.56), treatment-associated complications during current hospitalization (OR = 0.77, 98% CI = 0.45 to 1.32; <i>P</i> = 0.35), development of <i>Clostridium difficile</i>-associated diarrhea (OR = 3.29, 98% CI = 0.77 to 22.4; <i>P</i> = 0.14), or medication toxicity (OR = 2.07, 98% CI = 0.79 to 6.08; <i>P</i> = 0.15). <b>Conclusion and relevance:</b> The use of narrow-spectrum antibiotics for the empiric treatment of CA-IAI-reduced PTZ length of therapy and did not result in adverse clinical outcomes.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"42 1","pages":"16-22"},"PeriodicalIF":1.3,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12759147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Continuous Glucose Monitoring Into Pharmacy Elective Curriculum: A Practical Learning Experience.","authors":"Aia Gamal Eldin, Anna Nogid","doi":"10.1177/87551225251379742","DOIUrl":"10.1177/87551225251379742","url":null,"abstract":"<p><p><b>Background:</b> Pharmacists play a vital role in diabetes education, including continuous glucose monitors (CGMs). However, formal CGM training within pharmacy education remains limited. To address this, a CGM wear activity using the FreeStyle Libre 3 system was integrated into a third-year (P3) pharmacy elective. <b>Objective:</b> To evaluate how a week-long educational CGM wear experience affects P3 students' knowledge and confidence in using CGMs and influences their empathy toward patients with diabetes. <b>Methods:</b> This was a prospective, single-center study. Students enrolled in the course attended a lecture on CGMs and were invited to wear a FreeStyle Libre 3 sensor for 1 week. During the sensor-wear period, students completed daily tasks simulating the management of a patient with diabetes. Preactivity and postactivity surveys were administered to evaluate changes in knowledge (9 items), confidence (5 items), and empathy (6 items) related to CGMs and diabetes care. Change in knowledge was assessed using a paired <i>t</i> test while change in confidence and empathy were assessed using Wilcoxon signed-rank test. <b>Results:</b> Seventeen students participated in the wear experience, completed the presurvey and postsurvey, and were included in the analysis. Statistically significant increases were noted in the knowledge assessment scores (54.4% vs 70%, <i>P</i> < 0.005), all self-reported confidence items (<i>P</i> < 0.05), and 2 empathy items related to wearing the CGM sensor (<i>P</i> < 0.05). Students reported being woken up by the alarms as the biggest challenge. <b>Conclusions:</b> Following this week-long CGM wear activity, students demonstrated improved knowledge, confidence, and empathy related to CGMs and diabetes care.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"10-15"},"PeriodicalIF":1.5,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12534835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived Effectiveness of Employer-Provided Burnout Resources for Emergency Medicine and Critical Care Pharmacists.","authors":"Alivia E Castle, Roseanne Cohen, Kathy Weekes-Plante, Marika Krull, Peter Callas, Amanda G Kennedy","doi":"10.1177/87551225251380484","DOIUrl":"10.1177/87551225251380484","url":null,"abstract":"<p><p><b>Background:</b> Among health care professionals, burnout is of growing concern, affecting both personal well-being and professional performance. Burnout poses significant risks to patient care with diminished work quality and increased staff turnover. Factors contributing to burnout have been identified although specific preventative resources and accessibility data remain limited. <b>Objective:</b> This study aimed to evaluate burnout among emergency medicine and critical care pharmacists, and identify the availability and impact of employer-provided resources on burnout. <b>Methods:</b> This national survey aimed to describe burnout and preventative resource utilization among emergency medicine and critical care pharmacists. Responses were collected from December 20, 2024 to February 14, 2025 from self-identified critical care and emergency medicine pharmacists that accessed the survey from professional listserv posts or email invitations. Demographic information was collected, and burnout was assessed using the Oldenburg Burnout Inventory (range 16-64, with higher scores indicating more burnout). Descriptive statistics, Student's <i>t</i> tests, and analysis of variance (ANOVA) were used with statistical significance defined as <i>P</i> < 0.05. Multivariable linear regression models were used to understand the relationships among variables and burnout. Free text survey responses were reviewed and coded based on themes. <b>Results:</b> Among 346 completed surveys, 72.1% were submitted by female pharmacists, and 50% of respondents practice in emergency medicine. Moderate burnout was observed with a mean score of 39.1 (<i>SD</i> = 7.1). 46.4% of participants indicated using resources at least monthly with clinical support during shifts the most common. All multivariate models demonstrated an association between lack of peer support and burnout. The top resources pharmacists suggested for reducing burnout included improved scheduling, improved staffing ratios, and scheduled nonclinical time. <b>Conclusions:</b> Moderate burnout was observed among critical care and emergency medicine pharmacists with a strong desire for increased leadership support within staffing indicated. In addition, leaders should consider creating formal peer support programs to prevent or address burnout.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"69-77"},"PeriodicalIF":1.5,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12510997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Myopathy Associated with Entecavir Initiation.","authors":"Courtney Overton, Logan Brock, Bindu Betapudi, Drew A Wells","doi":"10.1177/87551225251382411","DOIUrl":"10.1177/87551225251382411","url":null,"abstract":"<p><p>Hepatitis B virus (HBV) infection can lead to severe complications, including cirrhosis, hepatocellular carcinoma, and death. Entecavir, a guanosine nucleoside analogue, is recommended for chronic hepatitis B virus (CHB) and is rarely associated with myopathy. This report presents a 65-year-old woman with CHB who developed suspected entecavir-associated myopathy. The patient, with a history of hypertension, systemic lupus erythematosus, rheumatoid arthritis, seizures, stroke, polyneuropathy, cervical and lumbar myelopathy, bilateral lumbar radiculopathy, and alcohol use, was admitted for chest pain. Acute pathologies were ruled out; however, acute reactivation of CHB was identified. Entecavir was initiated, but the patient developed significant fatigue and muscle weakness within days, in the absence of acute liver failure. On discontinuation of entecavir and initiation of tenofovir disoproxil fumarate, the patient's symptoms improved. This case highlights the rare but serious adverse effects of entecavir, emphasizing the need for careful monitoring and consideration of alternative treatments in patients with CHB.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"105-108"},"PeriodicalIF":1.5,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Interactions With Excessive Daytime Sleepiness Treatments.","authors":"Stanley V Thomas, Mark A Malesker, Daniel E Hilleman, Naresh A Dewan","doi":"10.1177/87551225251369328","DOIUrl":"10.1177/87551225251369328","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the potential for drug interactions with pharmacotherapy for central hypersomnolence (modafinil, armodafinil, solriamfetol, pitolisant, sodium oxybate, methylphenidate, amphetamine, lithium, clarithromycin). <b>Data Sources:</b> A systemic literature search (1980 to June 2025) was performed using PUBMED, SCOPUS, and EMBASE to locate relevant articles. The MeSH terms included specific medication and \"drug interactions.\" DAILYMED was used for product-specific interactions. <b>Study Selection and Data Extraction:</b> The search was conducted to identify drug interactions with excessive daytime sleepiness treatments. The search was limited to those articles studying humans and publications using the English language. Case reports, clinical trials, review articles, treatment guidelines, and package labeling were selected for inclusion. <b>Data Synthesis:</b> Primary literature and package labeling indicate that pharmacotherapy for central hypersomnolence is subject to both pharmacokinetic and pharmacodynamic interactions. While some interactions can be clinically significant, much of the data available for potential drug interactions was found in the package labeling and not from the primary literature. <b>Conclusions:</b> Available literature indicates that pharmacotherapy for central hypersomnolence is associated with clinically significant drug interventions and subsequent possible adverse reactions. Clinicians in all practice settings should be mindful of the potential to minimize drug interactions and optimize pharmacotherapy for hypersomnolence.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"38-47"},"PeriodicalIF":1.5,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Risk of Intracranial Hemorrhage With Tenecteplase Versus Alteplase in Acute Ischemic Stroke.","authors":"Katherine Hammaker, Stephanie Bills, Taylor H Cason, Nicholas J Quinn, Rhonda Cadena, Alyssa Lear","doi":"10.1177/87551225251377987","DOIUrl":"10.1177/87551225251377987","url":null,"abstract":"<p><p><b>Background:</b> In patients with acute ischemic stroke (AIS), tenecteplase and alteplase help preserve brain tissue. The 2019 American Heart Association/American Stroke Association guidelines designate alteplase as the first-line therapy for AIS, listing tenecteplase as a reasonable alternative for patients eligible for mechanical thrombectomy. The 2023 European Stroke Organisation recommends tenecteplase in patients with AIS due to large vessel occlusion prior to thrombectomy. Our institution adopted tenecteplase as the formulary fibrinolytic for AIS due to emerging clinical data, reduced cost, and operational benefits. <b>Objective:</b> The objective was to compare outcomes associated with tenecteplase versus alteplase in AIS. <b>Methods:</b> This multicenter, retrospective study included adults treated with tenecteplase or alteplase for AIS between April 1, 2022 and April 1, 2023. The primary outcome was intracranial hemorrhage (ICH) within 36 hours. Secondary outcomes included hospital and intensive care unit length of stay, in-hospital all-cause mortality, door-to-needle time, time to reperfusion, and adverse events. A subgroup analysis was performed to assess ICH that required reversal therapies. <b>Results:</b> There was no significant difference in the incidence of ICH between the tenecteplase and alteplase groups (20.4% vs 11.7%; <i>P</i> = 0.09). Within the subgroup analysis, a higher proportion of patients in the tenecteplase group required reversal therapies for ICH compared with the alteplase group (35.0% vs 8.3%; <i>P</i> = 0.09). Secondary outcomes were similar between groups. <b>Conclusion</b>: There was no significant difference in the incidence of ICH after tenecteplase or alteplase administration. Further studies are warranted to clarify the comparative safety profiles of tenecteplase and alteplase.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"23-29"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extending Universal Licensing Recognition (ULR) Laws to Licensure Renewal: A Pharmacist Case Study.","authors":"Alex Adams, Edward J Timmons","doi":"10.1177/87551225251375346","DOIUrl":"10.1177/87551225251375346","url":null,"abstract":"<p><p>Universal Licensing Recognition (ULR) laws have emerged as a key policy tool to improve license mobility by allowing licensure obtained in one state to be more easily recognized in another. While these reforms have increased access to licensure and employment opportunities, they generally apply only to initial licensure, not to renewal. Nearly all state boards of pharmacy require continuing education (CE) for license renewal, yet CE requirements vary significantly across states in terms of hours, topics, formats, reporting frequency, and approved providers. These discrepancies create substantial administrative burdens for pharmacists maintaining active licenses in multiple jurisdictions. This article examines the implications of extending ULR principles to license renewal, using a case study of a pharmacist licensed in West Virginia and neighboring states. The analysis suggests that pharmacists working across state lines often default to the most restrictive CE standards to ensure compliance, incurring unnecessary cost and complexity. We highlight Idaho's 2024 reform to its ULR statute, which exempts multistate licensees from duplicative CE requirements if they comply with their home state's CE standards and limits overall CE burdens based on regional averages. These reforms offer a promising model for pharmacy regulators seeking to reduce administrative friction, support workforce flexibility, and enhance access to care without compromising professional standards.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"52-57"},"PeriodicalIF":1.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Therapeutic Plasma Exchange on Apixaban Plasma Levels.","authors":"David Hensler, Danielle Burghardt","doi":"10.1177/87551225251369344","DOIUrl":"10.1177/87551225251369344","url":null,"abstract":"<p><p><b>Objective:</b> Therapeutic plasma exchange (TPE) may enhance the elimination of drugs from human plasma. Removal of apixaban during TPE has not been extensively described previously. <b>Case:</b> This is a retrospective report of a 76-year-old man admitted to the hospital on apixaban with acute worsening of respiratory and bulbar symptoms due to myasthenia gravis. On hospital day (HOD) 1, TPE was initiated for management of myasthenic crisis. Apixaban levels were obtained before and after a TPE session on HOD 3. On HOD 3, the patient's apixaban plasma level decreased from 88 ng/mL before TPE to 81 ng/mL after. Apixaban displayed an elimination half-life of 65.5 hours with intervening TPE. <b>Discussion/conclusions:</b> We report no clinically significant apixaban removal in a patient undergoing TPE for myasthenic crisis. This differs from previous reports. Supplemental dosing or rescheduling of apixaban doses around TPE sessions may be unnecessary, though more data are needed.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"48-51"},"PeriodicalIF":1.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct Oral Anticoagulant Transition Strategies Using Anti-Xa Concentrations Upon Intensive Care Unit Admission.","authors":"Mariah I Sigala, Corey V Dinunno, Chelsea N Lopez, Luma Succar, Jenny H Petkova, Edward A Graviss, Duc T Nguyen, Kevin R Donahue","doi":"10.1177/87551225251372486","DOIUrl":"10.1177/87551225251372486","url":null,"abstract":"<p><p><b>Background:</b> The increased utilization of oral factor Xa inhibitors (FXaI) has led to a growing interest in the clinical utility of FXaI-specific anti-Xa concentrations. Critically ill populations are at risk of bleeding secondary to FXaI accumulation in the setting of end-organ dysfunction. To mitigate this risk, an FXaI anti-Xa concentration-guided approach to transitioning between oral and parenteral anticoagulation has been explored. <b>Objective:</b> To compare the incidence of bleeding upon intensive care unit (ICU) admission between 2 different FXaI transition strategies: concentration versus non-concentration-guided. <b>Methods:</b> We performed a retrospective chart review of patients admitted between January 2019 and May 2022 with objective evidence of FXaI exposure within 48 hours preceding ICU admission. Patients were excluded if they were admitted to the ICU with a primary diagnosis related to a bleeding event, received a non-FXaI anticoagulant 48 hours preceding ICU admission, remained off anticoagulation during their ICU admission, or underwent surgical procedures. The primary outcome was the incidence of major bleeding within 5 days of ICU admission. Thromboembolic events were evaluated as a secondary endpoint. <b>Results:</b> A total of 433 patients (184 concentration-guided vs 249 non-concentration-guided) were included. There was no difference in major bleeding between groups (2.7% in concentration-guided vs 3.6% in non-concentration-guided; <i>P</i> = 0.79). Thromboembolic complications were similar between groups (1.6% in concentration-guided vs 2.0% in non-concentration-guided; <i>P</i> = 1.00) despite a longer time from last FXaI dose to anticoagulant transition in the concentration-guided group (29.9 hours vs 19.4 hours; <i>P</i> < 0.01). <b>Conclusion and relevance:</b> Use of FXaI concentrations to guide anticoagulation transition in the ICU had no impact on major bleeding events or thromboembolic complications. Further analyses are needed to validate FXaI concentration-guided strategies and solidify anti-Xa cutoffs to create a standardized approach to FXaI transitions in the critically ill patient population.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"3-9"},"PeriodicalIF":1.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of an Interruptive Alert on the Number of Women Receiving CDC-Recommended Therapy for Trichomoniasis.","authors":"Nicole Sunshine, Rachel M Kenney, Nathan A Everson, Christen J Arena, Erin Eriksson, Brian M Church, Jacob Manteuffel, Michael P Veve","doi":"10.1177/87551225251369348","DOIUrl":"10.1177/87551225251369348","url":null,"abstract":"<p><p><b>Background:</b> The 2021 Centers of Disease Control and Prevention (CDC) sexually transmitted infection treatment guidelines recommend a 7-day course of metronidazole or single-dose tinidazole for women with trichomoniasis due to improved patient outcomes compared with single-dose metronidazole therapy. A health system antimicrobial stewardship program implemented an interruptive electronic health record (EHR) alert to promote optimal trichomoniasis prescribing when nonrecommended treatment is ordered. <b>Objective:</b> To determine the impact of an interruptive EHR alert on optimal trichomoniasis prescribing for women. <b>Methods:</b> This was an institutional review board-approved, single pretest, posttest quasi-experiment of women ≥15 years with a microbiologically confirmed <i>Trichomonas vaginalis</i> infection from 10/2023 to 12/2023 (preintervention) and 10/2024 to 12/2024 (postintervention). An EHR alert was implemented 9/2024 that notifies prescribers that single-dose metronidazole 2 g is not recommended and suggests CDC-recommended treatments. The primary outcome was the proportion of single-dose metronidazole 2 g orders before and after EHR alert implementation. A secondary cross-sectional evaluation of all alerts triggered from 10/2024 to 12/2024 was performed and included the number of alerts, location of alert, and provider response. <b>Results:</b> A total of 285 patients were included, 49.8% pre-intervention and 50.2% postintervention. Metronidazole 2 g was prescribed for 8.45% of pre-intervention and 2.80% of postintervention patients (<i>P</i> = 0.038). The clinical support alert fired 102 times for 75 patients during the 3-month postimplementation period. The alert was associated with a change in intended prescription to a metronidazole 7-day course in greater than 60% of patients over 3 months. <b>Conclusion:</b> The implementation of an interruptive alert was associated with high acceptance and improved prescribing for women treated for trichomoniasis.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"63-68"},"PeriodicalIF":1.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}